KNSA - Company ID 0001730430
The table below shows Kiniksa Pharmaceuticals, Ltd.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $189.95M | $174.86M | $192.04M | $157.13M | $97.38M | $99.27M |
| Short-term investments | $278.14M | $177.24M | $115.75M | $111.21M | $126.40M | $119.49M |
| Receivables | $23.22M | $51.74M | $31.91M | $40.06M | $24.89M | $20.45M |
| Inventory | $73.14M | $41.40M | $48.18M | $22.07M | $28.68M | $34.86M |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $594.17M |
| $475.53M |
| $420.31M |
| $355.91M |
| $311.30M |
| $301.02M |
| Property, plant & equipment | $1.99M | $1.66M | $1.08M | $606.00K | $561.00K | $625.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $825.28M | $712.33M | $661.15M | $599.33M | $555.30M | $542.43M |
| Accounts payable | $24.40M | $6.15M | $8.96M | $1.98M | $8.33M | $7.39M |
| Total current liabilities | $156.61M | $123.59M | $117.83M | $97.27M | $95.95M | $84.29M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $219.59M | $176.95M | $166.14M | $141.84M | $118.29M | $107.33M |
| Retained earnings | -$439.55M | -$476.34M | -$494.77M | -$512.60M | -$512.25M | -$499.56M |
| Total equity | $605.69M | $535.38M | $495.01M | $457.49M | $437.01M | $435.10M |